References
- Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow S, Campo E, HarrisNL, et al. , editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 214–217.
- Isaacson PG, Du MQ. MALT lymphoma – from morphology to molecules. Nat Rev Cancer 2004;4:644–653.
- Raderer M, Wöhrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa associated lymphoid tissue lymphoma using extensive staging: a single center experience. J Clin Oncol 2006;24:3136–3141.
- Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741–2745.
- Martinelli G, Laszlo D, Ferreri A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979–1983.
- Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306–310.
- Raderer M, Wöhrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine, and prednisolone in patients with relapsed MALT lymphoma. Oncology 2006;70:411–417.
- Salar A, Domingo-Domenech E, Estary C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009;115:5210–5217.
- Illidge T, Chan C. How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? Leuk Lymphoma 2008;49:1263–1273.
- Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no addtional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
- Esmaeli B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90-ibritumomab tiuxetan (Zevalin) for front line treatment of early stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 2009;20:709–714.
- Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma. Hell J Nucl Med 2008;11:12–15.
- Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010;34:184–189.